Head-to-head studies Insulin lispro Sanofi vs Humalog
Similar mean HbA1C reduction2,3
Similar mean HbA1C reduction from baseline to Week 26 in Insulin lispro Sanofi and Humalog groups, in both Type 1 and Type 2 diabetes2,3
Similar long-term safety and tolerability profiles2,3
Similar rates of patients with at least one hypoglycaemic event, regardless of the category, was observed in both Insulin lispro Sanofi and Humalog groups in Type 1 and Type 2 diabetes2,3
CI, confidence interval; EU, European Union; GIR, glucose infusion rate; HbA1c, glycated haemoglobin; INS, plasma insulin lispro concentration; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.
- Kapitza C, et al. Diabetes Obes Metab. 2017;19(5):622–7
- Garg SK, et al. Diabetes Technol Ther. 2017;19(9):516–26
- Derwahl K, et al. Diabetes Technol Ther. 2018;20(1):1–10
Always up to date?
Webinars, evidence, expert video’s, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.